Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Glargine vs Pioglitazone Add-on in T2DM
NCT00384215Phase 4Completed
- Sponsor
- Sanofi
- Start
- Dec 2001
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change in Hemoglobin A1c at 48 weeks. Started Dec 2001; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00384215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384215.